Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Kimmel: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial.... (0.08 sec) 

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial …

- annals.org
SE Kimmel, JA Berlin, M Reilly, J Jaskowiak, L … - Annals of internal medicine, 2005 - Am Coll Physicians
Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective
inhibitors affect cardiovascular risk through various mechanisms. Some of these
mechanisms could increase risk (for example, inhibition of prostacyclin ...
Cited by 197 - Related articles - All 15 versions

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of …

- annals.org
LE Levesque, JM Brophy, B Zhang - Annals of internal medicine, 2005 - Am Coll Physicians
Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed
since 1999 as safer alternatives to nonsteroidal anti-inflammatory drugs
(NSAIDs). Debate about their cardiac safety has culminated in the recent ...
Cited by 193 - Related articles - All 15 versions

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute …


M Mamdani, P Rochon, DN Juurlink, GM … - Archives of Internal Medicine, 2003 - archinte.highwire.org
Methods We conducted a population-based retrospective cohort study using
administrative health care data from Ontario, Canada, from April 1, 1998, to
March 31, 2001. We identified NSAID-naive cohorts of subjects aged 66 years ...
Cited by 252 - Related articles - BL Direct - All 7 versions

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo- …

- mt.gov [PDF] 
DJ Graham, D Campen, R Hui, M Spence, C … - The Lancet, 2005 - Elsevier
We used data from Kaiser Permanente in California to assemble a cohort of all
patients age 18–84 years treated with a NSAID between Jan 1, 1999, and Dec 31,
2001, within which we did a nested case-control study. Cases of serious ...
Cited by 537 - Related articles - All 33 versions

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction …

- ahajournals.org
DH Solomon, S Schneeweiss, RJ Glynn, Y … - Circulation, 2004 - Am Heart Assoc
Methods and Results— We conducted a matched case-control study of 54 475
patients 65 years of age or older who received their medications through 2
state-sponsored pharmaceutical benefits programs in the United States. All ...
Cited by 445 - Related articles - BL Direct - All 14 versions

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and …


SP Johnsen, H Larsson, RE Tarone, JK … - Archives of Internal Medicine, 2005 - archinte.highwire.org
Methods Using data from hospital discharge registries in the counties of North
Jutland, Viborg, and Aarhus, Denmark, and the Danish Civil Registration System,
we identified 10 280 cases of first-time hospitalization for MI and 102 797 ...
Cited by 193 - Related articles - All 7 versions

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of …


FT Shaya, SW Blume, CM Blanchette, MR Weir … - Archives of Internal Medicine, 2005 - archinte.highwire.org
Background The differential effects of selective cyclooxygenase-2 (COX-2)
inhibitors compared with nonspecific nonsteroidal anti-inflammatory agents
(NSAIDs) on platelet aggregation and prostacyclin/thromboxane balance have ...
Cited by 61 - Related articles - All 8 versions

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart …


WA Ray, CM Stein, JR Daugherty, K Hall, PG … - The Lancet, 2002 - Elsevier
Results of premarketing and postmarketing trials have raised doubts about the
cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID)
rofecoxib, especially at doses greater than 25 mg. Between Jan 1, 1999, and ...
Cited by 437 - Related articles - All 9 versions

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or …

- bmj.com
J Hippisley-Cox, C Coupland - British Medical Journal, 2005 - bmj.com
Aims To determine the comparative risk of myocardial infarction in patients
taking cyclo-oxygenase-2 and other non-steroidal anti-inflammatory drugs
(NSAIDs) in primary care between 2000 and 2004; to determine these risks in ...
Cited by 325 - Related articles - All 14 versions

Lower risk of thromboembolic cardiovascular events with naproxen among patients with …


DJ Watson, T Rhodes, B Cai, HA Guess - Archives of Internal Medicine, 2002 - Am Med Assoc
Methods We studied patients aged 40 to 79 years with rheumatoid arthritis in the
British General Practice Research Database, excluding those with a prior TCE and
potentially confounding conditions. We matched up to 4 controls by sex, ...
Cited by 209 - Related articles - BL Direct - All 5 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google